UK markets closed

Unity Biotechnology, Inc. (UBX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.43-0.23 (-2.16%)
At close: 4:00PM EDT

Unity Biotechnology, Inc.

3280 Bayshore Boulevard
Suite 100
Brisbane, CA 94005
United States

Full-time employees100

Key executives

NameTitlePayExercisedYear born
Dr. Nathaniel E. DavidCo-Founder, Pres & Exec. Director640.86kN/A1968
Dr. Anirvan GhoshDirector & CEON/AN/A1964
Dr. Jan M. van DeursenFounderN/AN/AN/A
Dr. Judith CampisiFounderN/AN/AN/A
Mr. Daohong Zhou M.D.FounderN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.

Corporate governance

Unity Biotechnology, Inc.’s ISS governance QualityScore as of 8 December 2019 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more